BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Keck ML, Wrensch F, Pierce BG, Baumert TF, Foung SKH. Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine. Front Immunol 2018;9:1194. [PMID: 29904384 DOI: 10.3389/fimmu.2018.01194] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Law JLM, Logan M, Joyce MA, Landi A, Hockman D, Crawford K, Johnson J, LaChance G, Saffran HA, Shields J, Hobart E, Brassard R, Arutyunova E, Pabbaraju K, Croxen M, Tipples G, Lemieux MJ, Tyrrell DL, Houghton M. SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1. Vaccine 2021;39:5769-79. [PMID: 34481699 DOI: 10.1016/j.vaccine.2021.08.081] [Reference Citation Analysis]
2 Wrensch F, Keck ZY, Foung SKH, Baumert TF. Learning from a clinical cohort for HCV vaccine development. J Hepatol 2019;71:9-11. [PMID: 30992137 DOI: 10.1016/j.jhep.2019.03.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Velázquez-Moctezuma R, Augestad EH, Castelli M, Holmboe Olesen C, Clementi N, Clementi M, Mancini N, Prentoe J. Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies. Vaccines (Basel) 2021;9:291. [PMID: 33804732 DOI: 10.3390/vaccines9030291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chen F, Tzarum N, Wilson IA, Law M. VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design. Curr Opin Virol 2019;34:149-59. [PMID: 30884330 DOI: 10.1016/j.coviro.2019.02.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 15.0] [Reference Citation Analysis]
5 Prentoe J, Bukh J. Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry. Front Immunol 2018;9:2146. [PMID: 30319614 DOI: 10.3389/fimmu.2018.02146] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
6 Bonsignori M, Marcotrigiano J. HCV neutralization goes elite. Immunity 2022;55:195-7. [PMID: 35139349 DOI: 10.1016/j.immuni.2022.01.010] [Reference Citation Analysis]
7 Kardani K, Sadat SM, Kardani M, Bolhassani A. The next generation of HCV vaccines: a focus on novel adjuvant development. Expert Rev Vaccines 2021;20:839-55. [PMID: 34114513 DOI: 10.1080/14760584.2021.1941895] [Reference Citation Analysis]
8 Sevvana M, Keck Z, Foung SK, Kuhn RJ. Structural perspectives on HCV humoral immune evasion mechanisms. Curr Opin Virol 2021;49:92-101. [PMID: 34091143 DOI: 10.1016/j.coviro.2021.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Keck ZY, Pierce BG, Lau P, Lu J, Wang Y, Underwood A, Bull RA, Prentoe J, Velázquez-Moctezuma R, Walker MR, Luciani F, Guest JD, Fauvelle C, Baumert TF, Bukh J, Lloyd AR, Foung SKH. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. PLoS Pathog 2019;15:e1007772. [PMID: 31100098 DOI: 10.1371/journal.ppat.1007772] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
10 Augestad EH, Castelli M, Clementi N, Ströh LJ, Krey T, Burioni R, Mancini N, Bukh J, Prentoe J. Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity. Sci Adv 2020;6:eabb5938. [PMID: 32923643 DOI: 10.1126/sciadv.abb5938] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
11 Law M. Antibody Responses in Hepatitis C Infection. Cold Spring Harb Perspect Med 2021;11:a036962. [PMID: 32341067 DOI: 10.1101/cshperspect.a036962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Crooke SN, Ovsyannikova IG, Kennedy RB, Poland GA. Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome. Sci Rep 2020;10:14179. [PMID: 32843695 DOI: 10.1038/s41598-020-70864-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 16.5] [Reference Citation Analysis]
13 Mailly L, Wrensch F, Heydmann L, Fauvelle C, Brignon N, Zeisel MB, Pessaux P, Keck ZY, Schuster C, Fuerst TR, Foung SKH, Baumert TF. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection. Antiviral Res 2019;162:136-41. [PMID: 30599173 DOI: 10.1016/j.antiviral.2018.12.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
14 Olbrich A, Wardemann H, Böhm S, Rother K, Colpitts CC, Wrensch F, Baumert TF, Berg T, Benckert J. Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C. J Infect Dis 2019;220:1209-18. [PMID: 31165162 DOI: 10.1093/infdis/jiz274] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
15 Frumento N, Flyak AI, Bailey JR. Mechanisms of HCV resistance to broadly neutralizing antibodies. Curr Opin Virol 2021;50:23-9. [PMID: 34329953 DOI: 10.1016/j.coviro.2021.07.003] [Reference Citation Analysis]
16 Brisse M, Vrba SM, Kirk N, Liang Y, Ly H. Emerging Concepts and Technologies in Vaccine Development. Front Immunol 2020;11:583077. [PMID: 33101309 DOI: 10.3389/fimmu.2020.583077] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
17 Yechezkel I, Law M, Tzarum N. From Structural Studies to HCV Vaccine Design. Viruses 2021;13:833. [PMID: 34064532 DOI: 10.3390/v13050833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 He L, Tzarum N, Lin X, Shapero B, Sou C, Mann CJ, Stano A, Zhang L, Nagy K, Giang E, Law M, Wilson IA, Zhu J. Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines. Sci Adv 2020;6:eaaz6225. [PMID: 32494617 DOI: 10.1126/sciadv.aaz6225] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]